Charles Schwab Investment Management Inc. Has $10.79 Million Holdings in STAAR Surgical (NASDAQ:STAA)

Charles Schwab Investment Management Inc. lifted its holdings in shares of STAAR Surgical (NASDAQ:STAA - Free Report) by 4.3% in the fourth quarter, according to the company in its most recent filing with the Securities & Exchange Commission. The fund owned 444,290 shares of the medical instruments supplier's stock after buying an additional 18,168 shares during the period. Charles Schwab Investment Management Inc. owned 0.90% of STAAR Surgical worth $10,792,000 at the end of the most recent reporting period.

A number of other institutional investors have also modified their holdings of the business. Geode Capital Management LLC boosted its stake in STAAR Surgical by 2.7% in the third quarter. Geode Capital Management LLC now owns 1,174,499 shares of the medical instruments supplier's stock valued at $43,641,000 after acquiring an additional 31,212 shares during the period. HighTower Advisors LLC acquired a new position in STAAR Surgical during the 3rd quarter valued at approximately $336,000. Polar Asset Management Partners Inc. boosted its position in STAAR Surgical by 44.3% during the 3rd quarter. Polar Asset Management Partners Inc. now owns 168,800 shares of the medical instruments supplier's stock valued at $6,271,000 after purchasing an additional 51,800 shares during the period. JPMorgan Chase & Co. grew its stake in STAAR Surgical by 411.7% during the 3rd quarter. JPMorgan Chase & Co. now owns 214,750 shares of the medical instruments supplier's stock worth $7,978,000 after buying an additional 172,779 shares during the last quarter. Finally, Defender Capital LLC. increased its position in STAAR Surgical by 3.5% in the fourth quarter. Defender Capital LLC. now owns 701,567 shares of the medical instruments supplier's stock worth $17,041,000 after buying an additional 23,950 shares during the period. Institutional investors own 96.70% of the company's stock.

Remove Ads

Insiders Place Their Bets

In other STAAR Surgical news, major shareholder Broadwood Partners, L.P. bought 259,616 shares of the company's stock in a transaction dated Wednesday, February 12th. The shares were bought at an average price of $14.96 per share, for a total transaction of $3,883,855.36. Following the acquisition, the insider now directly owns 11,137,623 shares of the company's stock, valued at approximately $166,618,840.08. This trade represents a 2.39 % increase in their ownership of the stock. The acquisition was disclosed in a document filed with the SEC, which can be accessed through this hyperlink. Insiders bought a total of 1,070,483 shares of company stock worth $17,837,670 over the last ninety days. 1.00% of the stock is currently owned by company insiders.

STAAR Surgical Stock Up 0.6 %

Shares of NASDAQ STAA traded up $0.11 during mid-day trading on Wednesday, hitting $17.57. 812,933 shares of the company traded hands, compared to its average volume of 766,108. STAAR Surgical has a 1 year low of $13.50 and a 1 year high of $52.68. The stock has a market capitalization of $866.64 million, a price-to-earnings ratio of -42.85 and a beta of 0.66. The business has a 50 day moving average of $19.69 and a two-hundred day moving average of $25.43.

Wall Street Analysts Forecast Growth

STAA has been the subject of several analyst reports. BTIG Research downgraded shares of STAAR Surgical from a "buy" rating to a "neutral" rating in a report on Wednesday, February 12th. Jefferies Financial Group lowered shares of STAAR Surgical from a "buy" rating to a "hold" rating in a research note on Wednesday, February 12th. Piper Sandler dropped their price target on shares of STAAR Surgical from $40.00 to $16.00 and set a "neutral" rating on the stock in a research note on Wednesday, February 12th. Needham & Company LLC reaffirmed a "hold" rating on shares of STAAR Surgical in a report on Thursday, February 27th. Finally, Stephens reissued an "equal weight" rating and issued a $17.00 price objective on shares of STAAR Surgical in a report on Tuesday, March 18th. Two research analysts have rated the stock with a sell rating, eight have given a hold rating and one has assigned a buy rating to the company's stock. According to MarketBeat.com, STAAR Surgical has a consensus rating of "Hold" and an average target price of $25.29.

About STAAR Surgical

STAAR Surgical Company, together with its subsidiaries, designs, develops, manufactures, markets, and sells implantable lenses for the eye, and companion delivery systems to deliver the lenses into the eye. The company provides implantable Collamer lens product family (ICLs) to treat visual disorders, such as myopia, hyperopia, astigmatism, and presbyopia.